Immune Thrombocytopenia clinical trials at UC Davis

1 research study open to eligible people

PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
open to eligible people ages 1-18
This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.
Sacramento, California and other locations

Last updated: September 9, 2024